ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in Human Cancer Cell Lines

Zhenfeng Duan; Choy, Edwin; Harmon, David; Cao Yang; Ryu, Keinosuke; Schwab, Joseph; Mankin, Henry; Hornicek, Francis J.
September 2009
PLoS ONE;2009, Vol. 4 Issue 9, p1
Academic Journal
Background: ET-743 (trabectedin, Yondelis®) and PM00104 (Zalypsis®) are marine derived compounds that have antitumor activity. ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood. Methodology/Principal Findings: Human chondrosarcoma cell lines resistant to ET-743 (CS-1/ER) or PM00104 (CS-1/PR) were established in this study. The CS-1/ER and CS-1/PR exhibited cross resistance to cisplatin and methotrexate but not to doxorubicin. Human Affymetrix Gene Chip arrays were used to examine relative gene expression in these cell lines. We found that a large number of genes have altered expression levels in CS-1/ER and CS-1/PR when compared to the parental cell line. 595 CS-1/ER and 498 CS-1/PR genes were identified as overexpressing; 856 CS-1/ER and 874 CS-1/PR transcripts were identified as underexpressing. Three zinc finger protein (ZNF) genes were on the top 10 overexpressed genes list. These genes have not been previously associated with drug resistance in tumor cells. Differential expressions of ZNF93 and ZNF43 genes were confirmed in both CS-1/ER and CS-1/PR resistant cell lines by real-time RT-PCR. ZNF93 was overexpressed in two ET-743 resistant Ewing sarcoma cell lines as well as in a cisplatin resistant ovarian cancer cell line, but was not overexpressed in paclitaxel resistant cell lines. ZNF93 knockdown by siRNA in CS-1/ER and CS-1/PR caused increased sensitivity for ET-743, PM00104, and cisplatin. Furthermore, ZNF93 transfected CS-1 cells are relatively resistant to ET-743, PM00104 and cisplatin. Conclusions/Significance: This study suggests that zinc finger proteins, and ZNF93 in particular, are involved in resistance to ET-743 and PM00104.


Related Articles

  • Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein. Stordal, Britta; Hamon, Marion; McEneaney, Victoria; Roche, Sandra; Gillet, Jean-Pierre; O'Leary, John J.; Gottesman, Michael; Clynes, Martin // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array (TLDA) was used to characterise the expression of 380 genes...

  • The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Kvardova, Veronika; Hrstka, Roman; Walerych, Dawid; Muller, Petr; Matoulkova, Eva; Hruskova, Veronika; Stelclova, Dagmar; Sova, Petr; Vojtesek, Borivoj // Molecular Cancer;2010, Vol. 9, p147 

    Background: Cisplatin and its derivatives are commonly used anti-cancer drugs. However, cisplatin has clinical limitations including serious side effects and frequent emergence of intrinsic or acquired resistance. Thus, the novel platinum(IV) complex LA-12 represents a promising treatment...

  • In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. Olszewski, Ulrike; Ach, Florian; Ulsperger, Ernst; Baumgartner, Gerhard; Zeillinger, Robert; Bednarski, Patrick; Hamilton, Gerhard // Metal-Based Drugs;2009, Vol. 2009, p1 

    Platinum(IV) compounds like oxoplatin (cis, cis, trans-diammine-dichlorido-dihydroxido-platinum(IV)) show increased stability and therefore can be applied orally. In a panel of 38 human cancer cell lines this drug induced S-phase arrest and cell death with IC50 values 2.5-fold higher than...

  • Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. Hess, Suzanne M.; Mounce, Amanda M.; Sequeira, Russel C.; Augustus, Todd M.; Ackley, Margaret C.; Bierbach, Ulrich // Cancer Chemotherapy & Pharmacology;Oct2005, Vol. 56 Issue 4, p337 

    Recently, we reported a new class of DNA-targeted hybrid platinum-acridine agents. The parent intercalator, ACRAMTU, a 9-aminoacridine derivative, intercalates into the minor groove of DNA, causing the corresponding prototypical conjugate, PT-ACRAMTU (type I/ n=2), to form DNA adducts dissimilar...

  • Cellular responses induced by Cu(II) quinolinonato complexes in human tumor and hepatic cells. Tr vn¡ček, Zdeněk; Vančo, J n; Hošek, Jan; Bucht¡k, Roman; Dvoř k, Zdeněk // Chemistry Central Journal;2012, Vol. 6 Issue 1, p160 

    Background: Inspired by the unprecedented historical success of cisplatin, one of the most important research directions in bioinorganic and medicinal chemistry is dedicated to the development of new anticancer compounds with the potential to surpass it in antitumor activity, while having lower...

  • Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model. Modok, S.; Scott, R.; Alderden, R. A.; Hall, M. D.; Mellor, H. R.; Bohic, S.; Roose, T.; Hambley, T. W.; Callaghan, R. // British Journal of Cancer;7/16/2007, Vol. 97 Issue 2, p194 

    Four-coordinate (Pt(II)) platinum-based anticancer drugs are widely used in primary or palliative chemotherapy and produce considerable efficacy in certain clinical applications, for example testicular cancer. However, in many cancers the Pt(II) drugs are beset by poor efficacy mainly due to...

  • Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. McNeish, I. A.; Kanfer, E. J.; Haynes, R.; Giles, C.; Harland, S. J.; Driver, D.; Rustin, G. J. S.; Newlands, E. S.; Secki, M. J. // British Journal of Cancer;3/22/2004, Vol. 90 Issue 6, p1169 

    High-dose regimes containing etoposide, carboplatin and an oxazaphospharine can salvage 30-40% of patients with relapsed or refractory male germ cell tumours (GCTs). The additional benefit of paclitaxel in such high-dose therapy has not been tested. Between March 1995 and November 2002, 36 male...

  • The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line. WEIFENG ZHAO; SHUYUAN LIU; QIAN DOU; CHANGAN LI; JINGPEI DU; WEIHUA REN // Oncology Letters;Nov2015, Vol. 10 Issue 5, p3081 

    Drug resistance to cisplatin with continuous drug treatment is one of the most common causes of chemotherapy failure in hepatic carcinoma. Accumulating evidence suggests that WEE1 G2 checkpoint kinase (WEE1) is involved in cisplatin resistance, which has been demonstrated to correlate with...

  • Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation. Damia, Giovanna; Filiberti, Laura; Vikhanskaya, Faina; Carrassa, Laura; Taya, Yoichi; D'Incalci, Maurizio; Broggini, Massimo // Neoplasia;Jan2001, Vol. 3 Issue 1, p10 

    Posttranslational modifications of p53 induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines. Although both drugs were able to induce phosphorylation at serine 20 (Ser20), only DDP treatment induced p53 phosphorylation at...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics